^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) + Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1523P - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumour DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global phase III study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations (ID 2855)
Published date:
09/28/2019
Excerpt:
RAM+ERL potentially may delay the occurrence of resistance by the T790M mutation...Treatment with RAM+ERL resulted in superior PFS, with similar T790M rates at progression as compared to PL+ERL, suggesting the potential for effective EGFR-directed therapy after progression on RAM+ERL.
Trial ID:
Source:
Title:
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY)
Excerpt:
PFS is defined as the time from the date of randomization to the date of radiographically documented progressive disease (PD) based on investigator assessment, or the date of death due to any cause, whichever is first assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
Trial ID:
